Seroprevalence of antibodies against varicella zoster virus across all age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand

Figures & data

Table 1. Demographic characteristics of the participants included in this study (N = 950).

Sex	N (%)
Male	471 (49.58)
Female	479 (50.42)
Age group (years)	N (%)
<1	1 (0.11)
1–4	80 (8.42)
5–9	70 (7.37)
10–14	107 (11.26)
15–19	75 (7.89)
20–29	124 (13.05)
30–39	133 (14.00)
40–49	138 (14.53)
50–59	131 (13.79)
60–69	73 (7.68)
≥70	18 (18.95)
Past history of varicella	N (%)
Yes	268 (28.21)
No	633 (66.63)
Data not available/Uncertain	49 (5.16)
Previous varicella vaccination	N (%)
Yes	68 (7.16)
No	374 (39.37)
Data not available/Uncertain	508 (53.47)

Figure 1. Seropositivity rates and geometric mean titer (GMT) of anti-varicella zoster virus (anti-VZV) IgG in individuals across different age groups residing in Chonburi Province, Thailand (2022–2023).

The left y-axis represents the seropositivity rate; the right y-axis represents the GMT with means indicated as yellow squares. The numbers above yellow squares indicated GMT (IU/L). The number above the graph indicated the sample size in each age group.

Table 2. Seroprevalence of anti-VZV IgG by age group and sex.

Variables	N	Seropositivity rate N (%)	GMT (IU/L) (95% CI)	p-value (One-way ANOVA)
Total	950	616 (64.84)	187.90 (162.67–217.03)
Age groups (years)
<4	81	13 (16.1)	27.5 (19.5–38.7)	Reference
5–9	70	21 (30.0)	31.2 (19.5–50.1)	0.999
10–14	107	36 (33.6)	43.2 (28.7–65.1)	0.711
15–19	74	33 (44.6)	59.1 (33.3–104.9)	0.136
20–29	124	92 (74.2)	271.0 (184.0–399.0)	<0.001*
30–39	133	109 (81.9)	391.2 (281.2–544.3)	<0.001*
40–49	138	113 (81.9)	415.6 (305.5–565.3)	<0.001*
50–59	131	111 (84.7)	527.6 (387.4–718.6)	<0.001*
60–69	73	70 (95.9)	770.4 (576.2–1030.0)	<0.001*
≥70	18	18 (100.0)	1291.9 (802.9–2078.7)	<0.001*
Sex
Male	471	310 (65.8)	205.4 (167.8–251.5)	0.8862
Female	479	306 (63.9)	172.1 (140.1–211.5)

GMT, Geometric mean titer; CI, confidence interval; *, statistically significant.

Figure 2. Comparison of the VZV seroprevalence in the present study with the two previous studies conducted in Thailand in 1994 and 2014.

Data from 1994 and 2014 were previously published.^10,11 The asterisk indicated statistical significance at p < 0.05.

Migasena S, Simasathien S, Desakorn V, Phonrat B, Suntharasamai P, Pitisuttitham P, Aree C, Naksrisook S, Supeeranun L, Samakoses R, et al. Seroprevalence of varicella-zoster virus antibody in Thailand. Int J Infect Dis. 1997;2(1):26–30. doi:10.1016/S1201-9712(97)90007-2.

 Google Scholar

Thantithaveewat T, Thongmee T, Vichaiwattana P, Posuwan N, Suntharn P, Yoocharoen P, Tharmaphornpilas P, Poovorawan Y. Seroprevalence of varicella-zoster antibodies in a Thai population. Southeast Asian J Trop Med Public Health. 2019;50:94–100.

 Web of Science ®Google Scholar

Data availability statement

Data will be made available upon request.